Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145025 · ClinicalTrials.gov registry record
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
A clinical trial, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- 3
- Enrollment target
NCT03145025 is a clinical trial that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 3 participants.
The verdict
NCT03145025 has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
Interventions
- DEVICE Retisert
- DRUG Fluocinolone Acetonide Intravitreal Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2019-03-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03145025
The ClinicalTrials.gov registry entry for NCT03145025 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Retisert is the first listed.
NCT03145025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03145025 about?
NCT03145025 is a clinical study titled "Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant". An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
What is the current status of trial NCT03145025?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2017-07-14. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT03145025?
The interventions under investigation include: Retisert (DEVICE), Fluocinolone Acetonide Intravitreal Implant (DRUG).
Who is sponsoring clinical trial NCT03145025?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.